Publications by authors named "M-J Bergeron"
Article Synopsis
- - The study investigates the role of periostin (POSTN) in osteoarthritis (OA), finding it is increased in patients and linked to inflammation and cartilage breakdown, suggesting it could be a target for therapy.
- - Link N (LN), a peptide from link protein, is shown to have anabolic properties and can reduce inflammation and degradation in cartilage, leading the researchers to explore its effects on POSTN expression.
- - Experimental results reveal that LN can decrease POSTN expression and disrupt its signaling in chondrocytes, indicating it has potential as a therapeutic agent in treating OA by targeting POSTN.
Background: Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)-negative complete remission with combination chemotherapy. The addition of blinatumomab, a bispecific T-cell engager molecule that is approved for the treatment of relapsed, refractory, and MRD-positive BCP-ALL, may have efficacy in patients with MRD-negative remission.
Methods: In a phase 3 trial, we randomly assigned patients 30 to 70 years of age with -negative BCP-ALL (with :: indicating fusion) who had MRD-negative remission (defined as <0.
Methionine is an essential proteinogenic amino acid, but its excess can lead to deleterious effects. Inborn errors of methionine metabolism resulting from loss of function in cystathionine β-synthase (CBS) cause classic homocystinuria (HCU), which is managed by a methionine-restricted diet. Synthetic biotics are gastrointestinal tract-targeted live biotherapeutics that can be engineered to replicate the benefits of dietary restriction.
View Article and Find Full Text PDFLow-density lipoprotein cholesterol (LDL-C) reductions with the PCSK9 monoclonal antibody alirocumab may be affected by background statin dose due to increased PCSK9 levels with higher statin doses. Data from 8 Phase 3 trials conducted with background statin (n = 4629) were pooled by alirocumab dose (75 or 150 mg every 2 weeks) and control (placebo/ezetimibe), and analyzed by background statin type/dose. Overall, 58.
View Article and Find Full Text PDFArticle Synopsis
- High-fructose diets lead to increased de novo lipogenesis (DNL) and liver fat compared to isocaloric diets with complex carbohydrates, even without weight gain.
- The study involved eight healthy men monitored over 9 days using stable isotope tracers to evaluate liver fat synthesis and glucose production.
- Results showed that a high-fructose diet significantly raised both DNL and liver fat levels, indicating a negative impact on liver metabolism despite maintaining stable weight.
Background: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy.
Methods: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.